16:31 , May 4, 2018 |  BioCentury  |  Emerging Company Profile

Needling out Alzheimer’s

United Neuroscience Ltd.’s pipeline comprises immunotherapeutic vaccines that selectively stimulate B cell responses against endogenous neurotoxic proteins. Its lead candidate UB-311 is an anti-beta amyloid vaccine for Alzheimer’s disease designed to improve cognition while avoiding...
07:00 , Sep 12, 2016 |  BC Week In Review  |  Clinical News

CNP520: Phase II started

Novartis and Amgen began the double-blind, placebo-controlled, international Phase II Alzheimer’s Prevention Initiative (API) Generation Study to evaluate intramuscular CAD106 at weeks 1, 7 and 13 and quarterly thereafter or once-daily oral CNP520 for >=5...
07:00 , Sep 12, 2016 |  BC Week In Review  |  Clinical News

CAD106: Phase II started

Novartis and Amgen Inc. (NASDAQ:AMGN, Thousand Oaks, Calif.) began the double-blind, placebo-controlled, international Phase II Alzheimer’s Prevention Initiative (API) Generation Study to evaluate intramuscular CAD106 at weeks 1, 7 and 13 and quarterly thereafter or...
07:00 , Sep 14, 2015 |  BioCentury  |  Strategy

Mind melding

Novartis AG's third neuroscience deal of the summer checks two boxes for the pharma by sharing the risk for a BACE inhibitor program and adding another late-stage program in neurology, all without increasing the pharma's...
07:00 , May 4, 2015 |  BC Week In Review  |  Company News

Cytos, Novartis deal

Novartis will pay Cytos CHF4 million ($4.2 million) to eliminate payment obligations for CAD106 , an Alzheimer’s disease (AD) vaccine the companies discovered under a 2001 deal. Novartis is developing the vaccine containing beta amyloid...
07:00 , Aug 11, 2014 |  BC Week In Review  |  Company News

Novartis, Banner Alzheimer’s Institute (BAI) deal

Novartis partnered with not-for-profit BAI to evaluate two of the pharma’s compounds in cognitively healthy adults who have two genetic copies of the apolipoprotein E (APOE) epsilon 4 allele and are, according to the pharma,...
07:00 , Jul 28, 2014 |  BioCentury  |  Product Development

Still betting on Abeta?

This month's Phase II data neither proved nor disproved AC Immune S.A. 's hypothesis that it could dial out enough toxicity in crenezumab to enable a higher, more efficacious dose for AD than previous anti-...
00:46 , Jul 16, 2014 |  BC Extra  |  Company News

Novartis, Banner partner on Alzheimer's trial

Novartis AG (NYSE:NVS; SIX:NOVN) partnered with not-for-profit Banner Alzheimer's Institute (BAI) (Phoenix, Ariz.) to evaluate two of the pharma's compounds in cognitively healthy adults at risk of developing symptoms of Alzheimer's disease because they have...
07:00 , May 9, 2013 |  BC Innovations  |  Targets & Mechanisms

AD vaccine redux

Researchers at Harvard Medical School have teamed up with vaccine maker Mercia Pharma Inc. to design a next-generation Alzheimer's disease vaccine with an adjuvant that promotes a beneficial anti-inflammatory response that the team hopes will...
07:00 , Oct 24, 2011 |  BioCentury  |  Product Development

AD pipeline: Immunotherapies

AD pipeline: Immunotherapies...